The clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory testing and pathological activation.
A platform can assist in matching teams of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs. Treatment plans for multiple-competitive symmetrical fat tumors require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of polycystic symmetric fatty tumors. The platform serves the China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.